Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 4/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 5/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | TET3 | O43151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.30 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.30 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.30 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16718784 | 0.88 | CSNK1D (0.36) | CSNK1ECSNK1D | |
| SCHEMBL16699389 | 0.84 | CASR (0.31) | CASRCSNK1ECSNK1D | |
| SCHEMBL16698729 | 0.78 | CD38 (0.31) | — | |
| SCHEMBL28611830 | 0.72 | CSNK1D (0.36) | CSNK1ECSNK1DPRMT5WDR77 | |
| SCHEMBL16699410 | 0.71 | CSNK1E (0.40) | CSNK1ECSNK1D | |
| SCHEMBL16700182 | 0.69 | — | — | |
| SCHEMBL16700861 | 0.69 | — | — | |
| SCHEMBL23778990 | 0.66 | CSNK1D (0.36) | CSNK1ECSNK1D | |
| SCHEMBL16700071 | 0.65 | CSNK1E (0.61) | CSNK1ECSNK1D | |
| SCHEMBL22615748 | 0.64 | USP30 (0.39) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | CASR 2782/4885CSNK1E 1/4885CSNK1D 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.